Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Il più grande studio epidemiologico di tutti i tempi sulle malattie venose croniche, comprendente 70.000 pazienti, mostra l'importanza di un trattamento tempestivo


News provided by

Servier

Sep 14, 2011, 03:00 ET

Share this article

Share toX

Share this article

Share toX

PRAGA, September 14, 2011 /PRNewswire/ --

- "La diagnosi precoce e il trattamento tempestivo delle malattie venose croniche sono indispensabili per impedire che la malattia progredisca a fasi cliniche più avanzate tra cui le ulcere venose"

Il programma VEIN CONSULT, il più grosso studio epidemiologico mai effettuato sulle malattie venose croniche, realizzato sotto gli auspici della UIP (Unione Internazionale di Flebologia) e sostenuto da un sovvenzionamento illimitato da parte del Gruppo di ricerca Servier, rappresenta un impegno formativo a livello internazionale per aumentare il livello di sensibilizzazione verso le MVC tra pazienti, specialisti e autorità sanitarie. È il primo studio ad analizzare un grosso numero di pazienti appartenenti a molti paesi di diverse aree geografiche (Europa, Medio Oriente, Estremo Oriente, America Centrale e America Latina) utilizzando le stesse domande e la stessa classificazione (classificazione CEAP).

I primi risultati del programma VEIN CONSULT mostrano che le malattie venose croniche hanno un impatto negativo significativo sulla vita professionale dei pazienti, comportando grosse perdite di produttività; il 15% dei pazienti affetti da malattie venose croniche è costretto infatti a perdere giorni di lavoro. Le MVC sono inoltre responsabili per la sofferenza fisica e psicologica dei pazienti, che si riflette in una riduzione della qualità della vita. Osserviamo un significativo peggioramento della qualità della vita man mano che aumenta la gravità della patologia. Ciò influisce direttamente sui costi legati alle MVC, quasi il 4% dei pazienti ha dovuto cambiare lavoro a causa della patologia venosa e più del 6% è stato ricoverato in ospedale.

Per la prima volta, i pazienti sintomatici vengono sottoposti a controlli e le MVC vengono tempestivamente diagnosticate, al fine di migliorare il trattamento.

Otto pazienti su dieci soffrono di malattie venose croniche dalle fasi iniziali a quelle più avanzate, come edema e ulcera. Grazie al programma VEIN CONSULT, possiamo misurare per la prima volta la prevalenza di pazienti con MVC solo con sintomi (dolore alle gambe, pesantezza, sensazione di gonfiore…). I risultati mostrano che il 20% dei primi partecipanti appartenenti a diversi paesi sono classificati come pazienti solo con sintomi, mentre il 61,2% rientra tra i pazienti con segni tangibili di malattie croniche venose (varici, vene varicose, edema e ulcera).

I pazienti non vanno spontaneamente dal medico per il dolore alle gambe e i medici non considerano il dolore alle vene una forma di malattia. Malgrado l'impatto delle malattie venose  croniche sui costi e sulla qualità della vita, i pazienti con malattie venose croniche non hanno ancora ricevuto una diagnosi e un trattamento.

"Il passaggio a fasi cliniche successive quando il trattamento inizia in fase già avanzata potrebbe provocare la perdita di giornate di lavoro, ridurre la qualità della vita e alzare i costi in generale" ha dichiarato il Professor Rabe, presidente dell'Unione Internazionale di Flebologia.

Il programma VEIN CONSULT durerà fino al 2012 in oltre 20 paesi. I risultati dell'analisi eseguita sui primi 70.000 pazienti appartenenti a 13 paesi (Brasile, Francia, Georgia, Ungheria, Messico, Pakistan, Romania, Russia, Serbia, Singapore, Slovacchia, Spagna e Emirati Arabi Uniti) sono stati presentati durante una sessione interamente dedicata al Congresso UIP a Praga.

Il Comitato scientifico UIP

Note per il revisore:

Informazioni sull'Unione Internazionale di Flebologia (UIP)

L'Unione Internazionale di Flebologia è un'organizzazione internazionale che ha l'obiettivo di migliorare l'eccellenza e l'innovazione nelle malattie venose e linfatiche mediante la formazione, la consulenza e la ricerca.

Il programma VEIN CONSULT è tenuto sotto gli auspici dell'UIP ed è supportato da un sovvenzionamento illimitato da parte del Gruppo di ricerca Servier.

Riferimenti:

Rabe E. Aggiornamento sul programma Vein Consult: il programma di sensibilizzazione più grande al mondo per le malattie venose croniche. Estratto pubblicato come supplemento di Flebologia pratica, capitolo europeo dell'incontro di UIP, Praga, Repubblica Ceca, 14-17 settembre 2011.

Puskas A. Primi risultati su 70000 pazienti analizzati tramite assistenza sanitaria di base all'interno del programma Vein Consult. Estratto pubblicato come supplemento di Flebologia pratica, capitolo europeo dell'incontro di UIP, Praga, Repubblica Ceca, 14-17 settembre 2011.

Mansilha A. Qualità della vita e costi delle malattie venose croniche: primi risultati del Programma Vein Consult. Estratto pubblicato come supplemento di Flebologia pratica, capitolo europeo dell'incontro di UIP, Praga, Repubblica Ceca, 14-17 settembre 2011.

Fernandez Quesada F. Primi risultati dei pazienti seguiti dagli specialisti nel programma Vein Consult. Estratto pubblicato come supplemento di Flebologia Pratica, capitolo europeo dell'incontro di UIP, Praga, Repubblica Ceca, 14-17 settembre 2011.

21%

more press release views with 
Request a Demo

Modal title

Also from this source

Voranigo® (vorasidenib) de Servier recibe premios Prix Galien en varias regiones

Voranigo® (vorasidenib) de Servier recibe premios Prix Galien en varias regiones

Servier, grupo farmacéutico internacional independiente regido por una fundación, anunció hoy que Voranigo® (vorasidenib) ha sido galardonado con el...

Voranigo® (Vorasidenib) von Servier erhält Prix Galien Awards in mehreren Regionen

Voranigo® (Vorasidenib) von Servier erhält Prix Galien Awards in mehreren Regionen

Servier, ein unabhängiger internationaler Pharmakonzern, der von einer Stiftung geleitet wird, gab heute bekannt, dass Voranigo® (Vorasidenib) bei...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Medical Equipment

Medical Equipment

Surveys, Polls and Research

Surveys, Polls and Research

News Releases in Similar Topics

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.